Figure S1a. NK cells and serum cooperate in mediating rituximab-induced B cell depletion. Same experiment as shown in Fig. 3; all samples and controls are shown. -/+ RTX, without/with rituximab. Figure S1b. The extent of rituximab-induced B cell depletion correlates with the size of NK cell proportions. Same experiment as shown in Fig. 4a; the complete experiment with all negative controls including proof of successfull NK cell depletion is shown. -/+ RTX, without/with rituximab. (ZIP 421 kb
CD56dim NK cells do not respond to CCR2 ligands. NK cells were incubated in the absence (–) or prese...
Figure S1. MCAM expression on NK cells does not correlate with clinical score. Percentages of MCAM-e...
Figure S1. MHC Class-I profile in K562, CAKI-1, SN12C, A498 and 786-O cells. The expression of MHC-I...
Figure S1. Representative flow cytometric plot of NK cell cytotoxic activity. PKH-26 was used to gat...
<p>Rituximab increases killing frequency of IL-2 activated NK cells. 221 target cells were treated w...
Background: Rituximab has broad and increasing application in rheumatic diseases. It is known from l...
<p>Increasing the killing frequency of fresh NK cells by cytokines and Rituximab. (A) Freshly isolat...
Introduction: Rituximab is a monoclonal antibody used to treat hematological malignancies. The antib...
Figure S1. Dot Plot visualizing the purity of NK cells after negative isolation by MACS. PBMCs befor...
<p>L3055 B cells were exposed to HCVcc JFH-1 for 2 hours, washed to remove non-associated virus and ...
NK cell phenotype and cytotoxicity in relation to immunosuppressive treatment. Patients and methods ...
Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...
Figure S4. (A) Representative flow cytometry analysis of CD112/CD155 expression on B16F10 melanoma c...
OBJECTIVE: In the last few years, anti-CD20 antibody rituximab profoundly changed the therapeutic la...
Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...
CD56dim NK cells do not respond to CCR2 ligands. NK cells were incubated in the absence (–) or prese...
Figure S1. MCAM expression on NK cells does not correlate with clinical score. Percentages of MCAM-e...
Figure S1. MHC Class-I profile in K562, CAKI-1, SN12C, A498 and 786-O cells. The expression of MHC-I...
Figure S1. Representative flow cytometric plot of NK cell cytotoxic activity. PKH-26 was used to gat...
<p>Rituximab increases killing frequency of IL-2 activated NK cells. 221 target cells were treated w...
Background: Rituximab has broad and increasing application in rheumatic diseases. It is known from l...
<p>Increasing the killing frequency of fresh NK cells by cytokines and Rituximab. (A) Freshly isolat...
Introduction: Rituximab is a monoclonal antibody used to treat hematological malignancies. The antib...
Figure S1. Dot Plot visualizing the purity of NK cells after negative isolation by MACS. PBMCs befor...
<p>L3055 B cells were exposed to HCVcc JFH-1 for 2 hours, washed to remove non-associated virus and ...
NK cell phenotype and cytotoxicity in relation to immunosuppressive treatment. Patients and methods ...
Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...
Figure S4. (A) Representative flow cytometry analysis of CD112/CD155 expression on B16F10 melanoma c...
OBJECTIVE: In the last few years, anti-CD20 antibody rituximab profoundly changed the therapeutic la...
Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...
CD56dim NK cells do not respond to CCR2 ligands. NK cells were incubated in the absence (–) or prese...
Figure S1. MCAM expression on NK cells does not correlate with clinical score. Percentages of MCAM-e...
Figure S1. MHC Class-I profile in K562, CAKI-1, SN12C, A498 and 786-O cells. The expression of MHC-I...